Condition
Candida Albicans Infection
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 3 (1)
Trial Status
Unknown2
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05289375Not ApplicableNot Yet Recruiting
Efficacy of the Vacucis Candida® Autovaccine
NCT06146504Not ApplicableCompleted
Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement
NCT04837664Phase 3UnknownPrimary
Curcumin; Rose Bengal; Denture Stomatitis
NCT03462862Not ApplicableUnknownPrimary
Evaluation of Candida Albicans Growth on BreFlex Versus PEEK Denture Base in Maxillary Bounded Partial Denture
Showing all 4 trials